iTeos Announces Clinically Meaningful Objective Response Rate Observed at Every Dose in Follow-up Interim Analysis of GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients

6 days ago

- Clinically meaningful objective response rate ( ORR ) of 63.3-76.7% observed with belrestotug + dostarlimab combinations, with confirmed ORR ( cORR ) at ~60% for every dose- >30% cORR difference between belrestotug + dostarlimab vs dostarlimab monotherapy- Belrestotug + dostarlimab safety ...

Ticker	Sentiment	Impact
ITOS	Neutral	12 %